Expression of Cyclooxygenase-2 and Transforming Growth Factor-Beta 1 in Patients with the Early Recurrence of Hepatocellular Carcinoma Following Hepatectomy

Background: Cyclooxygenase-2 (COX-2) and transforming growth factor-beta1 (TGF-β1) are modulated in variety cancers including Hepatocellular carcinoma (HCC). However, there is a paucity of data concerning their role in the pathologic process of recurrence of HCC following hepatectomy. We herein assessed the role of the hepatic expression of COX-2 and TGF-β as predictors for patients with early recurrence within 2 years of HCC diagnosis. Methods: Sixty patients with HCC who underwent curative hepatectomy between 2000 and 2003 were entered in the present study. The immunoreactivity and distribution patterns of COX-2 and TGF-β1 were examined in both the HCC and the adjacent nonHCC tissues of the liver. Risk factors of tumor recurrence within 2 years, including COX-2 and TGF-β1 expression, were investigated by univariate and multivariate analyses. Results: Among 60 patients, 31 patients had early recurrences within 2 years and 14 patients recurred after 2 years following surgery. Patients with low COX-2 expression in the HCC tissues and adjacent nonHCC tissues had favorable disease-free survival (p = 0.002 and p β1 expression in the nonHCC tissues had also longer disease-free survival (p = 0.045). Based on the expression patterns of COX-2 and TGF-β1, patients with low COX-2 and positive TGF-β1 expression in the nonHCC tissues had favorable overall and disease-free survival (p β1 signaling in nontumor tissues suggested high risk of recurrence and poor survival to the HCC patients following hepatectomy.

Expression of insulin-like growth factor-1 mRNA and protein level of corpora striata in ischemic side at the early stage of middle cerebral artery ischemia/reperfusion in rhesus monkeys

BACKGROUND： Insulin-like growth factor-I（IGF-1）, as one of the important members of growth factor family, participants in the regulation of many physiological functions and behaviors, having very strong neuroprotective effect. However, the expression of IGF-1 following cerebral ischemia/reperfusion is still disputed. OBJECTIVE： To observe the expression of IGF-1 and protein of corpora striata in ischemic side at the early stage of middle cerebral artery ischemia/reperfusion in rhesus monkey. DESIGN ： A completely randomized grouping design, controlled animal experiment SETTING ： Institute of Cerebrovascular Disease, Affiliated Hospital of Medical College of Qingdao University MATERIALS： ① Totally 17 rhesus monkeys , of either gender, aged 4 to 5 years, were enrolled . Seven rhesus monkeys observed with gene chip were randomly divided into 2 groups： sham operation group （n=3） and ischemia/reperfusion group 〈n=4〉. Ten rhesus monkeys observed with in situ hybridization and immunohistochemistry method were randomly divided into 2 groups： sham operation group 〈n=3 〉and ischemia/reperfusion group （n=7）. Rhesus monkeys observed under microscope were divided into 2 groups： sham operation group （n=6） and ischamia/reperfusion group （n=-11）.②Materials used in the experiment： cresyl violet （Sigma Company, America）; immunohistochemical reagent kit （ Huamei Bio-engineering Company）; In situ hybridization reagent kit （Boshide Bio-engineering Co.Ltd, Wuhan）; 12 800 dots chip （Boxing Company, Shanghai）. METHODS ： This experiment was carried out at the Institute of Cerebrovascular Disease, Affiliated Hospital of Medical College of Qingdao University from January 2001 to December 2003.① The onset area of middle cerebral artery was blocked for 2 hours, middle cerebral artery ischemia/reperfusion models were created.② After ischemia/reperfusion for 24 hours, cerebral tissue sections of rhesus monkeys were prepared and stained with cresyl violet. Image analysis was performed with 5001W image analysis software. Morphological change of corpora striata of operative side was observed in the rhesus monkeys between two groups. Total RNA was extracted from cerebral tissue. ③ Detection of gene chip： Cy3-duTP and Cy5-duTP were used to respectively perform reverse transcription labeling. The sample was reversely transcribed into cDNA, then hybridized with cDNA of cerebral tissue. Genes with the separate absolute value of cy3 and cy5〉800, cY3/cy5 〉 2（high expression） or 〈 0.5 （low expression） were found out. Those were genes with differential expression. ④ The expressions of IGF-1 mRNA and protein level of corpora striata in ischemic side of rhe- sus monkeys were detected between sham operation group and ischemia/reperfusion group at 9 and 24 hours after ischemia/reperfusion with in situ hybridization method and immunohistochemical method. Brown granules were IGF-1 protein positive cells. ⑤ Analysis of variance was used in the difference comparison of measurement data among groups. MAIN OUTCOME MEASURES ： ① Change of morphological structure of corpora striata at ischemic side in rhesus monkeys. ② Change of cerebral gene expression profiles at ischemia/reperfusion in rhesus monkeys between two groups.③ Expression of IGF-1 mRNA and protein level of corpora striata at ischemia/reperfu- sion in rhesus monkeys between two groups. RESULTS ： ① Pathological change ： Obvious pathological change of cerebral infarction appeared in the ischemia and reperfusion group, while there was no such pathological change in the sham operation group.② Change of gene expression profile ： There were 4480 genes with difference expression in the ischemia/reperfusion group and sham-operation group, in which, 260 genes had high expression and their absolute value was over 800, and 63 genes had low expression, cy3/cy5 of IGF-1 was 0.379, being relative low ex- pression. ③ IGF-1 mRNA and protein positive cell counts in corpora striata at cerebral ischemic side[IGF-1 mRNA： 〈9.72±1.18）,（9.11 ±0.76）,（14.77±0.60） counts/field：lGF-1 protein： （15.11 ±1.83）,（15.39±0.78）, （34.62±0.97）counts/field, P 〈 0.05-0.01]. CONCLUSION： IGF-1 mRNA and protein are lowly expressed in middle cerebral artery of rhesus monkeys at ischemia/reperfusion.

血管内皮生长因子、程序性死亡受体-1联合胃功能三项对早期胃癌的诊断及预后评估价值

目的:探讨血管内皮生长因子(VEGF)、程序性死亡受体-1(PD-1)联合胃功能三项对早期胃癌(EGC)的诊断及预后评估价值。方法:选取EGC患者167例为EGC组,对术中的胃癌及癌旁组织进行收集,免疫组织化学染色后比较VEGF、PD-1阳性表达情况。另选取本院同期体检健康者74例为对照组,比较EGC组与对照组胃功能三项[胃蛋白原Ⅰ(PGⅠ)、胃蛋白原Ⅱ(PGⅡ)和胃泌素17(G17)]水平。所有患者均进行为期3年随访,根据是否病死分为预后良好组和预后不良组,比较两组临床病理资料。Logistic回归分析EGC患者预后不良的影响因素,Pearson法分析各指标的相关性,受试者工作特征(ROC)曲线分析VEGF、PD-1联合胃功能三项检测在EGC患者诊断及预后评估中的应用价值。结果:EGC组患者癌旁组织VEGF、PD-1阳性表达率低于胃癌组织(均P<0.05)。与对照组比较,EGC组PGⅠ水平降低,PGⅡ、G17水平升高(均P<0.05)。根据随访结果,预后不良组59例,预后良好组108例。预后不良组患者VEGF和PD-1阳性表达率以及PGⅡ、G17水平高于预后良好组,中高分化占比和PGⅠ水平低于预后良好组(均P<0.05)。低PGⅠ水平、高VEGF和PD-1阳性表达率、低分化、高PGⅡ和G17水平是EGC患者预后不良的危险因素(均P<0.05)。VEGF、PD-1、PGⅡ、G17水平与分化程度呈负相关,PGⅠ水平与分化程度呈正相关(均P<0.05)。VEGF、PD-1联合胃功能三项检测对EGC患者均有一定的诊断和预后评估价值,联合检测的价值更高(均P<0.05)。结论:VEGF、PD-1在胃癌组织中高表达,两者联合胃功能三项对EGC的诊断和预后评估均有较高价值。

EGR-1和MMP-2在早期自然流产患者中的表达及临床意义

目的探讨早期生长反应因子(EGR-1)和基质金属蛋白酶-2(MMP-2)在早期自然流产患者绒毛中的表达及临床意义。方法采用RT-PCR和Westernblot检测20例早期自然流产患者(流产组)和20例正常早孕人工流产(对照组)绒毛组织中EGR-1和MMP-2的表达情况。结果流产组中EGR-1、MMP-2 mRNA和蛋白水平明显低于对照组,差异有统计学意义(P<0.05)。结论EGR-1和MMP-2在早孕绒毛组织中表达异常可能参与早期妊娠失败的发生。

三阴性乳腺癌组织中EGR1、AR、H3K4me3表达与其临床病理特征及预后的相关性

目的探讨三阴性乳腺癌组织中早期生长反应基因1(EGR1)、雄激素受体(AR)、组蛋白H3第4位赖氨酸三甲基化(H3K4me3)表达与其临床病理特征及预后的相关性。方法回顾性分析89例三阴性乳腺癌患者的临床资料,所有患者均行手术治疗,采用免疫组化染色法测定EGR1、AR、H3K4me3表达,比较肿瘤组织及癌旁正常组织内EGR1、AR、H3K4me3表达差异,分析EGR1、AR、H3K4me3表达与其临床病理的关系,分析EGR1、AR、H3K4me3表达与其预后的关系。结果肿瘤组织内EGR1阳性表达率、AR阳性表达率低于对照组,H3K4me3阳性表达率高于对照组,差异有统计学意义(P<0.05);EGR1阳性表达、AR阳性表达患者临床分期Ⅰ~Ⅱ期、无淋巴结转移、中高分化占比高于EGR1阴性表达、AR阴性表达患者,H3K4me3阳性表达患者临床分期Ⅲ期、淋巴结转移、低分化占比高于H3K4me3阴性表达患者,差异有统计学意义(P<0.05);随访1年,89例患者共36例出现复发转移,发生率为40.45%(36/89);复发转移组EGR1阳性表达、AR阳性表达率低于未复发转移组,H3K4me3阳性表达率高于未复发转移组,差异有统计学意义(P<0.05)。结论EGR1、AR在三阴性乳腺癌中多呈阴性表达,H3K4me3则以阳性表达为主,三者表达均与临床分期、淋巴结转移及分化程度存在密切关系,或可作为临床治疗的新靶点。

Transcription factor EGR-1 inhibits growth of hepatocellular carcinoma and esophageal carcinoma cell lines

AIM: The transcription factor EGR-1 (early growth response gene-1) plays an important role in cell growth, differentiation and development. It has identified that EGR-1 has significant transformation suppression activity in some neoplasms, such as fibrosarcoma, breast carcinoma. This experiment was designed to investigate the role of egr-1 in the cancerous process of hepatocellular carcinoma (HCC) and esophageal carcinoma (EC), and then to appraise the effects of EGR-1 on the growth of these tumor cells. METHODS: Firstly, the transcription and expression of egr-1 in HCC and EC, paracancerous tissues and their normal counterpart parts were detected by in situ hybridization and immunohistochemistry, with normal human breast and mouse brain tissues as positive controls. Egr-1 gene was then transfected into HCC (HHCC, SMMC7721) and EC (ECa109) cell lines in which no egr-1 transcription and expression were present. The cell growth speed, FCM cell cycle, plate clone formation and tumorigenicity in nude mice were observed and the controls were the cell lines transfected with vector only. RESULTS: Little or no egr-1 transcription and expression were detected in HCC, EC and normal liver tissues. The expression of egr-1 were found higher in hepatocellular paracancerous tissue (transcription level P=0.000; expression level P=0.143, probably because fewer in number of cases) and dysplastic tissue of esophageal cancer (transcription level P=0.000; expression level P=0.001). The growth rate of egr-1-transfected HHCC (HCC cell line) cells and ECa109 (EC cell line) cells was much slower than that of the controls. The proportion of S phase cell, clone formation and tumorigenicity were significantly lower than these of the controls' (decreased 45.5% in HHCC cells and 34.1% in ECa109 cells; 46.6% and 41.8%; 80.4% and 72.6% respectively). There were no obvious differences between SMMC7721 (HCC) egr-1-transfected cells and the controls with regard to the above items. CONCLUSION: The decreased expression of egr-1 might play a role in the dysregulation of normal growth in the cancerous process of HCC and EC. Egr-1 gene of transfected HHCC and ECa109 cells showed obvious suppression of the cell growth and malignant phenotypes, but no suppression in SMMC7721 (HCC cell line) cells.

Transactivation of the TIEG1 confers growth inhibition of transforming growth factor-β-susceptible hepatocellular carcinoma cells

AIM:To investigate the role of transforming growth factor(TGF)-β-inducible early gene 1(TIEG1) in TGF-β-induced growth inhibition in hepatocellular carcinoma(HCC) cells.METHODS:Human hepatocyte and HCC cell lines with varied susceptibilities to TGF-β1 were tested by methylthiazoletetrazolium(MTT) assay.The expression changes of Smad2,Smad3,Smad4,Smad7,TIEG1 and TIEG2 gene following treatment with TGF-β1 in a TGF-β-sensitive hepatocyte cell line(MIHA),a TGF-β-sensitive hepatoma cell line(Hep3B) and two TGF-β-insensitive hepatoma cell lines(HepG2 and Bel7404) were examined.SiRNA targeting TIEG1 was transfected into Hep3B cells and the sensitivity of cells to TGF-β1 was examined.Overexpression of TIEG1 was induced by lentiviral-mediated transduction in TGF-β1-resistant hepatoma cell lines(Bel7404 and HepG2).MTT assay and 4',6-Diamidino-2-phenylindole staining were used to identify cell viability and apoptosis,respectively.The expression level of stathmin was measured by reverse transcriptase polymerase chain reaction and Western-blotting analysis,and stathmin promoter activity by TIEG1 was monitored by a luciferase reporter gene system.RESULTS:TIEG1 was significantly upregulated by TGF-β1 in the TGF-β1-sensitive HCC cell line,Hep3B,but not in the resistant cell lines.The suppression of TIEG1 by siRNAs decreased the sensitivity of Hep3B cells to TGF-β1,whereas the overexpression of TIEG1 mediated growth inhibition and apoptosis in TGF-β1-resistant HCC cell lines,which resembled those of TGF-β1-sensitive HCC cells treated with TGF-β1.Our data further suggested that stathmin was a direct target of TIEG1,as stathmin was signif icantly downregulated by TIEG1 overexpression,and stathmin promoter activity was inhibited by TIEG1 in a dose-dependent manner.CONCLUSION:Our data suggest that transactivation of TIEG1 conferred growth inhibition of TGF-β-susceptible human HCC cells.

Insulin-like growth factor-binding protein-3 inhibits IGF-1-induced proliferation of human hepatocellular carcinoma cells

OBJECTIVE Basic fibroblast growth factor(b FGF)and platelet-derived growth factor(PDGF)produced by hepatocellular carcinoma(HCC)cells are responsible for the cell growth.Accumulating evidence shows that insulin-like growth factor-binding protein-3(IGFBP-3)suppresses HCC cell proliferation in both IGF-dependent and independent manners.The present study is to investigate whether treatment with exogenous IGFBP-3 inhibits bF GF and PDGF production and the cell proliferation of HCC cells.METHODS Cell Counting Kit 8 assay were designed to detect HCC cell proliferation,transcription factor early growth response-1(EGR1)involving in IGFBP-3 regulation of b FGF and PDGF were detected by RT-PCR and Western blot assays.Western blot assay was adopted to detect the IGFBP-3 regulating insulin-like growth factor 1 receptor(IGF-1R)signaling pathway.RESULTS The present study demonstrates that IGFBP-3 suppressed IGF-1-induced b FGF and PDGF expression while it does not affect their expression in the absence of IGF-1.To delineate the underlying mechanism,Western-blot and RT-PCR assays confirmed that the transcription factor early growth response protein 1(EGR1)is involved in IGFBP-3 regulation of b FGF and PDGF.IGFBP-3 inhibition of type 1 insulin-like growth factor receptor(IGF1R),ERK and AKT activation is IGF-1-dependent.Furthermore,transient transfection with constitutively activated AKT or MEK partially blocks the IGFBP-3 inhibition of EGR1,b FGF and PDGF expression.CONCLUSION In conclusion,these findings suggest that IGFBP-3suppresses transcription of EGR1 and its target genes b FGF and PDGF through inhibiting IGF-1-dependent ERK and AKT activation.It demonstrates the importance of IGFBP-3 in the regulation of HCC cell proliferation,suggesting that IGFBP-3 could be a target for the treatment of HCC.

转化生长因子-β_(1)相关血清微小核糖核酸对糖尿病肾病早期诊断的临床价值

目的探讨转化生长因子β_(1)(TGF-β_(1))相关血清微小核糖核酸(miRNA)对糖尿病肾病(DKD)早期诊断的临床价值。方法收集2019年1月至2021年12月在缙云县壶镇镇中心卫生院及缙云县人民医院就诊的2型糖尿病(T2DM)患者260例作为研究对象。根据尿白蛋白排泄率(UAER),研究对象分为单纯T2DM组135例、早期DKD组82例、临床DKD组43例。另选取50名健康志愿者作为对照组。检测各组血清miR-27a、miR-27b、miR-29c、miR-200c水平和TGF-β_(1)水平,并进行指标间的相关关系分析。利用受试者工作特征(ROC)曲线分析血清miRNAs对DKD的早期诊断价值。结果单纯T2DM组、早期DKD组和临床DKD组患者血清miR-27a、miR-27b、miR-200c水平及TGF-β_(1)水平均高于对照组,miR-29c水平低于对照组(F=235.624、70.351、108.127、672.304,P均<0.001)。TGF-β_(1)与血清miR-27a、miR-27b、miR-200c呈正相关,与miR-29c呈负相关(r=0.668、0.429、0.618、-0.502,P均<0.001)。血清miR-27a、miR-27b、miR-29c、miR-200c对T2DM患者发生DKD的诊断曲线下面积(AUC)为0.913、0.775、0.812、0.894,miR-27a和miR-200c的敏感度和特异度均>0.7。验证队列中血清miR-27a、miR-27b、miR-29c、miR-200c对T2DM患者发生DKD的诊断AUC分别为0.901、0.787、0.802、0.896,差异有统计学意义(Z=-9.012,P<0.01)。结论血清miR-27a、miR-27b、miR-29c、miR-200c对于早期DKD都有一定的诊断价值。

超早期小骨窗微创术对高血压脑出血VEGF、Ang-1和神经指标的影响

目的探讨超早期小骨窗微创术治疗高血压脑出血(hypertensive intracerebral hemorrhage,HICH)的疗效以及对患者血管内皮生长因子(vascular endothelial growth factor,VEGF)、血管生成素-1(angiopoietin-1,Ang-1)、神经功能影响。方法非随机选择2022年1月—2023年5月齐河县人民医院收治的90例HICH患者为研究对象,根据发病时间不同分成超早期组(n=45)、早期组(n=45)。两组患者均采取小骨窗微创术治疗,早期组患者在发病6~12 h实施手术,超早期组患者在发病6 h内实施手术。对比两组的治疗效果。结果超早期组治疗总有效率为95.56%(43/45),高于早期组的80.00%(36/45),差异有统计学意义(χ^(2)=5.074,P=0.024)。超早期组术后3 d的VEGF、Ang-1、神经元特异性烯醇化酶水平低于早期组,脑源性神经营养因子水平高于早期组,差异有统计学意义(P均<0.05)。超早期组并发症总发生率低于早期组,差异有统计学意义(P<0.05)。结论应用超早期小骨窗微创术治疗HICH的效果满意,降低血清VEGF、Ang-1水平,改善神经功能指标,术后并发症发生率低。

早期生长反应因子-1和组织因子在大鼠胰腺炎组织中的表达

目的观察早期生长反应因子-1(Egr-1)和组织因子(TF)在实验性大鼠急性胰腺炎组织中的表达。方法以大剂量雨蛙素(每小时腹腔注射20 μg/kg·b.w.,连续4 h)诱导建立大鼠急性实验性胰腺炎模型。观察刺激后30 min至4 h时急性胰腺炎组织Egr-1 mRNA和蛋白的表达以及TF mRNA的表达,并进行免疫组织化学检测。结果大剂量雨蛙素刺激后,大鼠胰腺呈典型的胰腺炎改变。刺激后30 min胰腺组织Egr-1 mRNA表达达到高峰,然后逐渐下降。但Egr-1蛋白水平在刺激后2 h达到高峰。组织学观察发现,刺激后2 h,几乎每个胰腺腺泡细胞均表达Egr-1蛋白,并大多集中在细胞核。TF mRNA的表达在刺激后1 h出现,并在4 h内逐渐增高。大剂量的蛙皮素刺激胰腺组织仅引起少量的Egr-1 mRNA的表达。结论Egr-1作为一种前炎性转录因子在急性胰腺炎的发生中可能起着重要的作用,这一作用在一定程度上可能是通过调节TF的表达而实现的。

Egr-1介导了IL-1β诱导的小鼠软骨细胞凋亡

目的:研究早期生长反应蛋白1(early growth response protein 1,Egr-1)在白细胞介素1β(interleu-kin-1β,IL-1β)诱导的软骨细胞凋亡中的作用。方法:体外分离培养小鼠关节软骨细胞,用IL-1β刺激不同的时间后,用Hoechst 33258染色,计算发生核皱缩细胞占全部细胞的比例;采用定量RT-PCR(qRT-PCR)方法检测Egr-1 mRNA表达水平;采用Western blotting方法检测Egr-1及激活型caspase-3蛋白的表达水平;采用Lipo-fectamine RNAiMAX将Egr选择性干扰片段转染软骨细胞,采用qRT-PCR及Western blotting观察RNA片段的干扰效率。结果:IL-1β刺激体外培养的软骨细胞4 h、8 h和12 h后,分别引起约7%、22%和41%细胞凋亡,同时激活型caspase-3表达上调。IL-1β诱导软骨细胞凋亡的同时,Egr-1 mRNA及蛋白质呈时间依赖的表达上调。2个siRNA片段成功干扰Egr-1表达后,细胞12 h凋亡率从约40%下降到14%和12%,同时激活型caspase-3的表达被有效抑制。结论:Egr-1介导了IL-1β诱导的软骨细胞凋亡,可能在骨关节炎的发病过程中发挥重要作用。

选择性环氧化酶-2抑制剂调节Egr-1作用机制的研究

目的:以肺腺癌细胞株A549为研究对象,观察不同浓度的塞来昔布对A549细胞的生长周期及凋亡率的影响,以及对早期反应基因-1(Early growth response-1,Egr-1)表达的影响,探讨环氧化酶-2(Cyclooxygenase-2,COX-2)抑制剂调节Egr-1的具体机制,从分子水平上寻找COX-2抑制剂抗肿瘤作用的具体机制,进一步指导临床治疗。方法:体外培养肺腺癌细胞A549,经25.0、50.0、100.0μmol/L浓度的塞来昔布处理细胞,24 h后采用流式细胞仪(Flowcytometer,FCM)测定细胞周期,TUNEL法测定细胞凋亡,RT-PCR法检测Egr-1、Fas基因的表达。结果:25.0、50.0、100.0μmol/L赛来昔布作用24 h后,A549细胞不同程度的阻滞在G0/G1期,A549细胞凋亡指数分别是10.67%±1.46%、18.33%±2.54%、25.67%±2.10%,差异具有统计学意义(P<0.05);随着塞来昔布药物浓度的增加,Egr-1和Fas的mRNA表达量逐步增加,差异具有统计学意义(P<0.05)。结论:高度选择性COX-2抑制剂塞来昔布可通过调节细胞周期和细胞凋亡发挥抗肿瘤作用,其作用机制可能是通过上调细胞中Egr-1的表达,进而上调Fas的表达,使细胞周期阻滞于G0/G1,最终促进细胞凋亡,这可能是环氧化酶抑制剂发挥抗癌作用的分子生物学基础。

血清胰岛素样生长因子-1检测对乳腺癌的诊断价值

目的:探讨胰岛素样生长因子-1(insulin-like growth factor1,IGF-1)对乳腺癌的诊断价值,寻找新的乳腺癌早期诊断标志物。方法:对45例经病理证实的乳腺癌及20例乳腺良性病变患者的术前外周血标本进行研究,以20例健康女性外周血标本作对照,应用免疫放射分析方法,定量检测IGF-1在血清中的含量。结果:对照组、乳腺良性病变组、乳腺癌组血清IGF-1值分别为136.50(63.07～190.23)ng/ml、60.02(20.46～151.20)ng/ml、165.50(76.89～584.18)ng/ml,乳腺癌组明显高于对照组(P<0.01),对照组与乳腺良性病变组无显著性差异(P>0.05)。乳腺癌组临床分期Ⅰ～Ⅱ期和Ⅲ～Ⅳ期患者血清IGF-1值分别为156.62(76.89～248.20)ng/ml、250.18(135.78～584.18)ng/ml;有、无淋巴结转移患者IGF-1值分别为224.87(103.28～584.18)ng/ml、139.78(76.89～243.68)ng/ml;IGF-1水平与乳腺癌的淋巴结转移和临床分期密切相关(P<0.01)。在乳腺癌组中雌激素受体阳性、阴性患者中血清IGF-1值分别为239.78(135.78～533.21)ng/ml、154.37(76.89～584.18)ng/ml,IGF-1水平在雌激素受体阳性组与阴性组有显著性差异(P<0.05)。结论:IGF-1的定量检测可提高对乳腺癌的诊断水平,IGF-1有望成为乳腺癌诊断的血清标志物。

胶质瘤egr-1基因表达水平与其细胞增殖和凋亡关系的研究

目的:探讨胶质瘤细胞egr-1基因表达水平与肿瘤恶性程度、细胞增殖活性及凋亡程度的关系。方法:用原位杂交、原位细胞凋亡检测和免疫组化染色方法观察了73例不同级别的胶质瘤。结果:73例胶质瘤egr-1 mRNA和EGR-1蛋白阳性表达率均为100%,这两种阳性肿瘤细胞密度均随肿瘤恶性程度升高而相应增加,不同级别组间比较差异均有显著性(P<0.01)。73例胶质瘤增殖细胞核抗原(PCNA)阳性肿瘤细胞和凋亡肿瘤细胞检出率均为100%。随肿瘤恶性程度升高,PCNA阳性肿瘤细胞密度增加而凋亡肿瘤细胞密度减少,不同级别组间比较差异均有显著性(P<0.05～0.01)。经直线相关分析证实,egr-1 mRNA、EGR-1蛋白和PCNA阳性肿瘤细胞密度彼此间均呈显著性正相关(r=0.685～0.999,P<0.01),前三种阳性肿瘤细胞密度均与凋亡肿瘤细胞密度呈显著性负相关(r=-0.758～-0.775,P<0.01)。结论:egr-1基因表达水平对评价胶质瘤生物学行为有重要参考价值。胶质瘤细胞egr-1基因表达异常增加可能是促进肿瘤细胞增殖和抑制其凋亡的重要因素,并在胶质瘤发生及恶性进展过程中均起重要作用。

外周血sFIt-1、β-hCG、PAPP-A、AFP的表达与早发型子痫前期的关系

目的探讨外周血可溶性血管内皮生长因子受体-1(sFIt-1)、人绒毛膜促性腺激素(β—hCG)、孕早期妊娠相关蛋白A(PAPP-A)、甲胎蛋白(AFP)的表达与早发型子痫前期(PE)的相关性。方法选取2014年10月—2015年10月武汉市第一医院收治的PE患者84例,其中早发型48例,迟发型36例。选择同期正常妊娠妇女80例为对照组。应用ELISA法测定所有研究对象外周血sFIt-1、β—hCG、PAPP—A、AFP水平,应用受试者特异性曲线(ROC)分析sFIt—1、β-hCG、PAPP-A、AFP对早发型子痫前期的诊断价值。结果早发型组PE患者外周血sFIt—1、β—hCG、PAPP—A、AFP水平均高于对照组(t=9.236、10.422、11.986、14.785,P<0.05),早发型组sFIt—1、PAPP—A、AFP水平高于迟发型组(t=9.236、7.458、10.252,P<0.05),而迟发型组外周血sFIt—1、PAPP-A、AFP与对照组比较差异无统计学意义(t=0.785、0.902、0.525,P>0.05)。早发型组重度PE外周血sFIt-1、β-hCG、PAPP-A、AFP水平均高于轻度患者(t=6.271、31.680、3.449、5.045,P<0.05),而迟发型组重度患者外周血sFIt-1、PAPP—A、AFP水平与轻度患者比较差异无统计学意义(t=0.598、0.230、0.437,P>0.05),而β-hCG比较差异有统计学意义(t=6.043,P<0.05)。经ROC分析可知,sFIt-1+β-hCG+PAPP—A+AFP联合诊断早发型PE的灵敏度及特异度高于单一指标检测。结论外周血sFIt-1、β—hCG、PAPP-A、AFP水平与早发型PE发生发展有密切的关系,早发型与晚发型PE可能存在不同的发病机制。通过联合应用多种指标诊断可提高早发型子痫前期患者诊断灵敏度。

bFGF,bFGFR及Egr-1基因蛋白在大鼠局灶性脑缺血后的表达

观察持续性局灶性脑缺血 (permanentmiddlecerebralarteryocclusion ,pMCAO)损伤后表达碱性成纤维细胞生长因子 (basicfibroblastgrowthfactor,bFGF)的细胞种类、时相与不同细胞之间的相互影响 ,并探讨Egr 1基因蛋白对bFGF表达的影响。结果表明 :在持续性局灶性脑缺血后 ,缺血梗死灶周边区免疫组化结果显示bFGF表达出现双相增强。缺血 1h缺血边缘区主要在星形胶质细胞 (Astrocyte,As)中bFGF出现一过性增强 ,并见细胞外基质中出现bFGF点状着色。缺血 6h～ 1d时bFGF染色再次增强 ,神经元及各类胶质细胞中的表达均有增强。但是经Western blot定量测定发现脑组织bFGF含量仅在缺血后 6h～ 1d时出现增强。缺血 1h时 ,bFGF可能经缺血细胞受损的细胞膜到达细胞外 ,与细胞外硫酸肝素或相关分子结合 ,内化进入缺血边缘区细胞 ,从而造成bFGF免疫组化染色一过性增强。第二次增强可能是缺血损伤刺激及内化的bFGF诱导的蛋白合成的增加。缺血 2～ 6hbFGFR在神经元及各类胶质细胞中的表达均增强 ,主要位于缺血区的边缘。由于bFGFR表达时程早于bFGF转录合成增加 ,因此限制了内源性bFGF发挥保护缺血损伤神经元的作用 ,这使得外源应用bFGF成为必要。Egr 1基因蛋白的表达在缺血损伤后 1～ 6h增强 ,其表达增高的时相早于bFGF?

后处理对缺血再灌注损伤大鼠肺Egr-1和IL-1β表达的影响

目的:研究后处理对在体缺血再灌注损伤大鼠肺早期生长反应因子1(Egr-1)和白细胞介素1β(IL-1β)表达的影响,并分析其可能的肺保护作用机制。方法:建立大鼠在体肺脏缺血再灌注损伤模型,将SD大鼠24只随机分为假手术(sham)组、缺血再灌注(I/R)组和缺血后处理(IPostC)组,每组8只。在体鼠I/R损伤模型制备完成后,阻断左肺门,终止血供及通气,造成左肺缺血,达预定时间后松开阻断带恢复血供及通气形成再灌注损伤。sham组只游离左侧肺门、套阻断带但不阻断,等待3 h后直接取标本;I/R组缺血1 h后再灌注2 h;IPostC组缺血1 h后给予重复3次的5 min灌注和5 min缺血的后处理,继以恢复血供行再灌注1.5 h。3组实验结束后均留取左侧肺组织,制成10%的组织匀浆,用于测定髓过氧化物酶(MPO)的含量;留取小块肺组织测定肺湿/干重比(W/D),并在光镜下观察肺组织的病理变化;RT-PCR法检测Egr-1 mRNA及IL-1βmRNA的表达量。结果:3组间各项检测指标比较,差异均显著(P<0.05)。与sham组比较,I/R组肺组织中Egr-1 mRNA、IL-1βmRNA的表达量、MPO的活性及W/D值均明显升高(P<0.05);肺组织炎症反应明显加重。IPostC组肺组织中Egr-1 mR-NA及IL-1βmRNA的表达量、MPO的活性及W/D值与I/R组相比均明显下降(P<0.05);肺组织炎症反应明显减轻。结论:后处理能够明显减轻大鼠肺缺血再灌注损伤,其机制可能与抑制Egr-1和IL-1β的表达有关。

组胺对星形胶质细胞Egr-1表达的调节作用

目的:探讨组胺对星形胶质细胞早期反应生长因子-1(Egr-1)表达是否具有调节作用。方法:将野生型(WT)和组氨酸脱羧酶敲除(HDC-KO)小鼠及组胺处理的HDC-KO小鼠取脑,并提取皮层组织总RNA。将原代培养的大鼠皮层星形胶质细胞分别给予不同浓度的组胺(10^(-8)、10^(-7)、10^(-6)、10^(-5)或10^(-4)mol/L)处理15、30、60、120或240 min。组胺H_1、H_2受体拮抗剂分别于组胺给药前15 min加入。组胺处理完毕后,提取细胞总RNA或蛋白。利用real-time PCR和Western blot测定Egr-1的表达。结果:与WT小鼠相比,HDC-KO小鼠大脑皮层Egr-1的mRNA表达量显著降低,而外源性给予组胺则能促进其Egr-1的mRNA表达。在培养的星形胶质细胞上,组胺可促进Egr-1的mRNA表达,其中10-5mol/L的组胺作用最强,而组胺(10^(-5)mol/L)处理30 min时Egr-1的mRNA表达量达到峰值,相应的Egr-1蛋白表达于60 min时显著增高,该作用可被组胺H_1受体拮抗剂而非H_2受体拮抗剂显著抑制。结论:组胺对大脑皮层组织及培养的星形胶质细胞Egr-1表达具有上调作用,该作用与激动组胺H_1受体有关。

EGR-1及MMP-9在子宫内膜异位症中的表达及意义

目的研究早期生长反应基因-1(EGR-1)与金属基质蛋白酶-9(MMP-9)在子宫内膜异位症患者异位内膜与在位内膜细胞中的表达情况及临床意义。方法收集45例2014年5月至2015年3月于四川省自贡市妇幼保健院确诊的子宫内膜异位症患者的异位内膜及在位内膜,同期收集30例非子宫内膜异位症患者的正常内膜组织。通过免疫组化二步法对三种内膜组织中EGR-1、MMP-9的表达情况进行分析。结果 EGR-1在子宫内膜异位症患者异位内膜(84.44%)与在位内膜(73.33%)腺上皮细胞中的阳性检测率显著高于正常内膜组(40.0%),差异有统计学意义(P<0.05),但两者差异无统计学意义(P>0.05);而不同内膜间质细胞中EGR-1的阳性检出率异位内膜为48.89%,在位内膜为44.44%,正常内膜为43.33%,三者比较差异无统计学意义(P>0.05);异位内膜和在位内膜腺上皮细胞(在位内膜88.89%、异位内膜64.44%)及间质细胞(在位内膜66.67%、异位内膜42.22%)中MMP-9的阳性检出率均显著高于正常内膜组(腺上皮细胞33.33%、间质细胞16.67%),差异均有显著统计学意义(P<0.01),且异位内膜组显著高于在位内膜组,差异有统计学意义(P<0.05)。结论检测EGR-1、MMP-9的表达可用于判断子宫内膜异位症的侵袭转移和评估预后。